| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Address correspondence and reprint requests to Dr. Steven R. Schwid, University of Rochester, Department of Neurology, 601 Elmwood Avenue, Box 605, Rochester, NY 14642; e-mail: steven_schwid{at}urmc.rochester.edu
Background: Cooling demyelinated nerves can reduce conduction block, potentially improving symptoms of MS. The therapeutic effects of cooling in patients with MS have not been convincingly demonstrated because prior studies were limited by uncontrolled designs, unblinded evaluations, reliance on subjective outcome measures, and small sample sizes.
Objective: To determine the effects of a single acute dose of cooling therapy using objective measures of neurologic function in a controlled, double-blinded setting, and to determine whether effects are sustained during daily cooling garment use.
Methods: Patients (n = 84) with definite MS, mild to moderate disability (Expanded Disability Status Scale score < 6.0), and self-reported heat sensitivity were randomized into a multicenter, sham-treatment controlled, double-blind crossover study. Patients had the MS Functional Composite (MSFC) and measures of visual acuity/contrast sensitivity assessed before and after high-dose or low-dose cooling for 1 hour with a liquid cooling garment. One week later, patients had identical assessments before and after the alternate treatment. Patients were then re-randomized to use the cooling garment 1 hour each day for a month or to have observation only. They completed self-rated assessments of fatigue, strength, and cognition during this time, and underwent another acute cooling session at the end of the period. After 1 week of rest, they had identical assessments during the alternate treatment.
Results: Body temperature declined during both high-dose and low-dose cooling, but high-dose produced a greater reduction (p < 0.0001). High-dose cooling produced a small improvement in the MSFC (0.076 ± 0.66, p = 0.007), whereas low-dose cooling produced only a trend toward improvement (0.053 ± 0.031, p = 0.09), but the difference between conditions was not significant. Timed gait testing and visual acuity/contrast sensitivity improved in both conditions as well. When patients underwent acute cooling following a month of daily cooling, treatment effects were similar. Patients reported less fatigue during the month of daily cooling, concurrently on the Rochester Fatigue Diary and retrospectively on the Modified Fatigue Impact Scale.
Conclusions: Cooling therapy was associated with objectively measurable but modest improvements in motor and visual function as well as persistent subjective benefits.
This article has been cited by other articles:
|
|
 |
|
  J. Pronk, G. Scheper, R. van Andel, C. van Berkel, C. Polman, B. Uitdehaag, and M. van der Knaap No evidence that polymorphisms of the vanishing white matter disease genes are risk factors in multiple sclerosis Multiple Sclerosis, September 1, 2008; 14(8): 1123 - 1126. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Schmitz-Hubsch, P. Giunti, D. A. Stephenson, C. Globas, L. Baliko, F. Sacca, C. Mariotti, M. Rakowicz, S. Szymanski, J. Infante, et al. SCA Functional Index: A useful compound performance measure for spinocerebellar ataxia Neurology, August 12, 2008; 71(7): 486 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Leigh and A. Serra Taking the temperature of MS with INO Neurology, March 25, 2008; 70(13_Part_2): 1063 - 1064. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kos, E. Kerckhofs, G. Nagels, M.B. D'hooghe, and S. Ilsbroukx Origin of Fatigue in Multiple Sclerosis: Review of the Literature Neurorehabil Neural Repair, February 1, 2008; 22(1): 91 - 100. [Abstract] [PDF]
|
|
|
|
|
|
D. Kos, M. Duportail, M. D'hooghe, G. Nagels, and E. Kerckhofs Multidisciplinary fatigue management programme in multiple sclerosis: a randomized clinical trial Multiple Sclerosis, September 1, 2007; 13(8): 996 - 1003. [Abstract] [PDF]
|
|
|
|
|
|
L. J. Balcer, S. L. Galetta, P. A. Calabresi, C. Confavreux, G. Giovannoni, E. Havrdova, M. Hutchinson, L. Kappos, F. D. Lublin, D. H. Miller, et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis Neurology, April 17, 2007; 68(16): 1299 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Meyer-Heim, M Rothmaier, M Weder, J Kool, P Schenk, and J Kesselring Advanced lightweight cooling-garment technology: functional improvements in thermosensitive patients with multiple sclerosis Multiple Sclerosis, March 1, 2007; 13(2): 232 - 237. [Abstract] [PDF]
|
|
|
|
|
|
S. R. Schwid and T. J. Murray Treating fatigue in patients with MS: One step forward, one step back Neurology, April 12, 2005; 64(7): 1111 - 1112. [Full Text] [PDF]
|
|
|
|
|
|
D Kos, E Kerckhofs, I Carrea, R Verza, M Ramos, and J Jansa Evaluation of the Modified Fatigue Impact Scale in four different European countries Multiple Sclerosis, February 1, 2005; 11(1): 76 - 80. [Abstract] [PDF]
|
|
|
|
 |
|
 Other articles noted: 25 Jul 03 to 7 Nov 03 Evid. Based Nurs., January 1, 2004; 7(1): e1 - 1. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
